New Market

Researchers are studying the effects of eluxadoline in children aged 6 to 17 years who have irritable bowel syndrome with diarrhea (IBS-D). This Phase 2 trial aims to explore how eluxadoline may help treat IBS-D symptoms in this age group, understand how the drug behaves in the body, and assess its safety and tolerability. Enrollment for children aged 12 to 17 has closed, but younger children aged 6 to 11 are still being enrolled. Participants will receive either oral eluxadoline tablets or matching placebo tablets. The study is randomized, double-blind, placebo-controlled, and dose-ranging, meaning neither the participants nor researchers know who receives the drug or placebo, and different doses may be tested. The trial includes multiple visits where treatments are administered, but specific dosing schedules are not detailed in the summary. Children taking part will complete electronic diaries to record symptoms like abdominal pain and stool consistency. Researchers will track changes in stool consistency over a 4-week treatment period compared to before treatment. Safety and tolerability will also be monitored throughout, with assessments including symptom evaluations and adherence to the diary. The total duration and further follow-up details are not specified.